Management of postthrombolysis hemor- rhagic and orolingual angioedema complications. Neurohospitalist. 153. Myslimi F, Caparros F, Dequatre-Ponchelle N, Moulin S, Gautier S, Girardie P, Cordonnier C, Bordet R, Leys D. Orolingual angioedema dur- ing or after thrombolysis for cerebral ischemia. Stroke. 2016;47:1825 154. Pahs L, Droege C, Kneale H, Pancioli A. A novel approach to the treatment of orolingual angioedema after tissue plasminogen ac- tivator administration. Ann Emerg Med. 2016;68:345 348. doi: 155. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014:CD000213. doi: 156. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 157. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. 158. Wahlgren N, Ahmed N, D valos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, et al; SITS- MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275 159. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, et al; IST-3 Collaborative Group. The benefits and harms of intravenous throm- bolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352 2363. doi: 160. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, Broderick JP, Chen X, Chen G, Sharma VK, et al; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intrave- nous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313 161. Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, Broderick JP, Sandercock P; PRISMS and IST-3 Collaborative Groups. Effect of intravenous recombinant tissue-type plasminogen ac- tivator in patients with mild stroke in the Third International Stroke Trial-3: post hoc analysis. Stroke. 2015;46:2325 2327. doi: 162. National Institute of Neurological Disorders Stroke rtPA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005;46:243 252. doi: 163. Ingall TJ, O Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. 164. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, BrottT, Cohen G, Davis S, Donnan G, et al; StrokeThrombolysisTrialists Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. 165. Bluhmki E, Chamorro A, D valos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 166. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P; SITS Investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 167. Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. JAMA Neurol. 168. Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, ChatterjeeA, Jauch EC, Levine SR, et al; PRISMS Investigators. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA. 2018;320:156 169. Adams RJ, Cox M, Ozark SD, Kanter J, Schulte PJ, XianY, Fonarow GC, Smith EE, Schwamm LH. Coexistent sickle cell disease has no impact on the safety or outcome of lytic therapy in acute ischemic stroke: findings from Get With The Guidelines Stroke. Stroke. 2017;48:686 691. doi: 170. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Janjua N, Divani AA. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology. 2006;66:1171 1174. doi: 171. IST Collaborative Group.Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute isch- aemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. Lancet Neurol. 2015;14:485 172. Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, PeetersA, FarrallAJ,AdamiA, Potter G, et al; IST-3 Collaborative Group. Effect of alteplase on the CT hyperdense artery sign and out- come after ischemic stroke. Neurology. 2016;86:118 125. doi: 173. Adeoye O, Sucharew H, Khoury J, Tomsick T, Khatri P, Palesch Y, Schmit PA, Pancioli AM, Broderick JP; for the CLEAR-ER, IMS III, and ALIAS Part 2 Investigators. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue- type plasminogen activator alone in acute ischemic stroke: propen- sity score-matched post hoc analysis. Stroke. 2015;46:461 464. doi: 174. Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, Levine SR, Demel S, Eckerle B, Katz B, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen ac- tivator in acute ischemic stroke: Full Dose Regimen Stroke Trial. Stroke. 175. Zinkstok SM, Roos YB; ARTIS Investigators. Early administra- tion of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380:731 737. doi: 176. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, Li Q, Billot L, Delcourt C, Bath PM, et al; ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. 177. Jeong HG, Kim BJ,Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. 178. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombec- tomy for ischemic stroke. N Engl J Med. 2018;378:1573 1582. doi: 179. Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase open-label, blinded endpoint study. Lancet Neurol. 2015;14:368 376. 180. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O Brien B, Bladin C, McElduff P, Allen C, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 181. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, et al; for the Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely termi- nated randomized clinical trial. Stroke. 2010;41:707 711. doi: 182. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, R nning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR- TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet 183. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, KasteM,LipkaLJ,PedrazaS,RinglebPA,etal.Intravenousdesmoteplase in patients with acute ischaemic stroke selected by MRI perfusion- diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 184. Hacke W,Albers G,Al-RawiY, Bogousslavsky J, DavalosA, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, et al; for the DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66 73. doi: 185. von Kummer R, Mori E, Truelsen T, Jensen JS, Gr nning BA, Fiebach JB, Lovblad KO, Pedraza S, Romero JM, Chabriat H, et al; for the DIAS-4 Investigators. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke. 2016;47:2880 2887. doi: 186. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gr nning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, et al; DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade ste- nosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14:575 584. doi: 187. Nacu A, Kvistad CE, Naess H, ygarden H, Logallo N, Assmus J, Waje-Andreassen U, Kurz KD, Neckelmann G, Thomassen L. NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): ran- domized controlled contrast-enhanced sonothrombolysis in an unsel- ected acute ischemic stroke population. Stroke. 2017;48:335 341. doi: 188. Alexandrov AV, K hrmann M, Soinne L, Tsivgoulis G, Barreto AD, Demchuk AM, Sharma VK, Mikulik R, Muir KW, Brandt G, et al; CLOTBUST-ER Trial Investigators. Safety and efficacy of sonothrom- bolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurol. 2019;18:338 347. doi: 189. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, D valos A, Majoie CB, van der Lugt A, de Miquel MA, et al; HERMES Collaborators. Endovascular thrombec- tomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723 1731. 190. Campbell BC, Hill MD, Rubiera M, Menon BK, Demchuk A, Donnan GA, Roy D, Thornton J, Dorado L, Bonafe A, et al. Safety and efficacy of solitaire stent thrombectomy: individual patient data meta-analysis of randomized trials. Stroke. 2016;47:798 806. doi: 191. Bush CK, Kurimella D, Cross LJ, Conner KR, Martin-Schild S, He J, Li C, Chen J, Kelly T. Endovascular treatment with stent-retriever devices for acute ischemic stroke: a meta-analysis of randomized con- trolledtrials.PLoSOne.2016;11:e0147287.doi:10.1371/journal.pone. 192. Turk AS 3rd, Siddiqui A, Fifi JT, De Leacy RA, Fiorella DJ, Gu E, Levy EI, Snyder KV, Hanel RA, Aghaebrahim A, et al. Aspiration throm- bectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet. 2019;393:998 193. Lapergue B, Blanc R, Gory B, Labreuche J, Duhamel A, Marnat G, Saleme S, CostalatV, Bracard S, Desal H, et al;ASTERTrial Investigators. Effect of endovascular contact aspiration vs stent retriever on revascular- ization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial. JAMA. 2017;318:443 452. doi: 194. Nogueira RG, Frei D, Kirmani JF, Zaidat O, Lopes D, Turk AS 3rd, Heck D, Mason B, Haussen DC, Levy EI, et al; Penumbra Separator 3D Investigators. Safety and efficacy of a 3-dimensional stent retriever with aspiration-based thrombectomy vs aspiration-based thrombectomy alone in acute ischemic stroke intervention: a randomized clinical trial. JAMA 195. Lemmens R, Hamilton SA, Liebeskind DS, Tomsick TA, Demchuk AM, Nogueira RG, Marks MP, Jahan R, Gralla J, Yoo AJ, et al; DEFUSE 2, IMS III, STAR, and SWIFT Trialists; DEFUSE 2 IMS III STAR and SWIFT Trialists. Effect of endovascular reperfusion in relation to site of arterial occlusion. Neurology. 2016;86:762 770. doi: 196. Yoo AJ, Simonsen CZ, Prabhakaran S, Chaudhry ZA, Issa MA, Fugate JE, Linfante I, Liebeskind DS, Khatri P, Jovin TG, et al; for the Cerebral Angiographic Revascularization Grading Collaborators. Refining angiographic biomarkers of revascularization: improving out- come prediction after intra-arterial therapy. Stroke. 2013;44:2509 2512. Bammer R, Albers GW; DEFUSE 2 Investigators. Correlation of AOL recanalization, TIMI reperfusion and TICI reperfusion with infarct growth and clinical outcome. J Neurointerv Surg. 2014;6:724 728. doi: 198. Berkhemer OA, van den Berg LA, Fransen PS, Beumer D, Yoo AJ, Lingsma HF, Schonewille WJ, van den Berg R, Wermer MJ, Boiten J, et al; MR CLEAN Investigators. The effect of anesthetic management during intra-arterial therapy for acute stroke in MR CLEAN. Neurology. 199. L whagen Hend n P, RentzosA, Karlsson JE, Rosengren L, Sundeman H, Reinsfelt B, Ricksten SE. Hypotension during endovascular treatment of ischemic stroke is a risk factor for poor neurological outcome. Stroke. 200. Sch nenberger S, Uhlmann L, Hacke W, Schieber S, Mundiyanapurath S, Purrucker JC, Nagel S, Klose C, Pfaff J, Bendszus M, et al. Effect of con- scious sedation vs general anesthesia on early neurological improvement among patients with ischemic stroke undergoing endovascular throm- bectomy: a randomized clinical trial. JAMA. 2016;316:1986 1996. doi: 201. Simonsen CZ, Yoo AJ, S rensen LH, Juul N, Johnsen SP, Andersen G, Rasmussen M. Effect of general anesthesia and conscious sedation dur- ing endovascular therapy on infarct growth and clinical outcomes in acute ischemic stroke: a randomized clinical trial. JAMA Neurol. 2018;75:470 202. Gory B, Haussen DC, Piotin M, Steglich-Arnholm H, Holtmannsp tter M, Labreuche J, Kyheng M, Taschner C, Eiden S, Nogueira RG, et al; Thrombectomy In TANdem lesions (TITAN) investigators. Impact of in- travenous thrombolysis and emergent carotid stenting on reperfusion and clinical outcomes in patients with acute stroke with tandem lesion treated with thrombectomy: a collaborative pooled analysis. Eur J Neurol. 203. Delgado F, Oteros R, Jimenez-Gomez E, Bravo Rey I, Bautista MD, Valverde Moyano R. Half bolus dose of intravenous abciximab is safe and effectiveinthesettingofacutestrokeendovasculartreatment.JNeurointerv 204. Heck DV, Brown MD. Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggres- sive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage. J Neurointerv Surg. 2015;7:170 175. doi: 205. Ernst M, Butscheid F, Fiehler J, Wittkugel O, Alfke K, Jansen O, Petersen D, Koch C, Eckert B. Glycoprotein IIb/IIIa inhibitor bridg- ing and subsequent endovascular therapy in vertebrobasilar occlu- sion in 120 patients. Clin Neuroradiol. 2016;26:169 175. doi: 206. Dippel DW, Majoie CB, RoosYB, van der Lugt A, van Oostenbrugge RJ, vanZwamWH,LingsmaHF,KoudstaalPJ,TreurnietKM,vandenBergLA, et al; for the MR CLEAN Investigators. Influence of device choice on the Powers et al 2019 Guidelines for Management of AIS e409 effect of intra-arterial treatment for acute ischemic stroke in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Stroke. 2016;47:2574 2581. 207. The International Stroke Trial (IST): a randomised trial of aspirin, subcu- taneous heparin, both, or neither among 19435 patients with acute isch- aemic stroke: International Stroke Trial Collaborative Group. Lancet. 1997;349:1569 1581. 208. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: ran- domised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641 1649. 209. Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplate- let therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 210. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al; CHANCE Investigators. Clopidogrel with as- pirin in acute minor stroke or transient ischemic attack. N Engl J Med. 211. Wang X, Zhao X, Johnston SC, Xian Y, Hu B, Wang C, Wang D, Liu L, Li H, Fang J, et al; CHANCE Investigators. Effect of clopidogrel with as- pirin on functional outcome in TIA or minor stroke: CHANCE substudy. 212. Pan Y, Wang Y, Wang Y. Author response: risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE. Neurology. 2017;89:2121 2122. doi: 10.1212/WNL. 213. Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, Liu L, MengX,WangA,WangC,etalY;onbehalfoftheCHANCEInvestigators. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: one-year outcomes. Circulation. 2015;132:40 214. WangY, Zhao X, Lin J, Li H, Johnston SC, LinY, PanY, Liu L, Wang D, Wang C, et al; CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk re- duction among patients with minor stroke or transient ischemic attack. 215. Jing J, Meng X, Zhao X, Liu L, Wang A, Pan Y, Li H, Wang D, Johnston SC, Wang Y, et al. Dual antiplatelet therapy in transient is- chemic attack and minor stroke with different infarction patterns: sub- group analysis of the CHANCE randomized clinical trial. JAMA Neurol. 216. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215 225. doi: 217. Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, R ther J, Witte OW, Hamann G, Junghans U, Villringer A, et al. Safety of Tirofiban in Acute Ischemic Stroke: the SaTIS trial. Stroke. 218. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, et al; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifiba- tide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 219. Johnston SC, Amarenco P. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:1395. doi: 220. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb- IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 221. Adams HP Jr, Effron MB, Torner J, D valos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, et al; for the AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). 222. Mokin M, Kass-Hout T, Kass-Hout O, Radovic V, Siddiqui AH, Levy EI, SnyderKV.Intravenousheparinforthetreatmentofintraluminalthrombus in patients with acute ischemic stroke: a case series. J Neurointerv Surg. 223. Vellimana AK, Kadkhodayan Y, Rich KM, Cross DT 3rd, Moran CJ, Zazulia AR, Lee JM, Chicoine MR, Dacey RG Jr, Derdeyn CP, et al. Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation. J Neurosurg. 2013;118:34 41. 224. Kate M, Gioia L, Buck B, Sivakumar L, Jeerakathil T, ShuaibA, Butcher K. Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation. Stroke. 2015;46:2685 2687. doi: 10.1161/ Sisson A, Pandurengan R, Chen Z, et al. The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: final results of a pilot safety study. 226. Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; on behalf of the ARTSS-2 Investigators. Randomized, mul- ticenter trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017;48:1608 1616. 227. Gioia LC, Kate M, Sivakumar L, Hussain D, Kalashyan H, Buck B, Bussiere M, Jeerakathil T, Shuaib A, Emery D, et al. Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic trans- formation: a prospective magnetic resonance imaging study. Stroke. 228. Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, hepa- rinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol. 2013;12:539 545. doi: 229. Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute isch- aemic stroke. Cochrane Database Syst Rev. 2015:CD000024. 230. Yi X, Lin J, Wang C, Zhang B, Chi W. Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deteri- oration and improving six-month outcome. J Stroke Cerebrovasc Dis. 231. Chang TS, Jensen MB. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2014:CD000103. 232. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose al- bumin treatment for acute ischaemic stroke (ALIAS) part 2: a ran- domised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. ALIAS Parts 1 and 2 and NETT Investigators. ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2. 234. Guluma KZ, Liebeskind DS, Raman R, Rapp KS, Ernstrom KB, Alexandrov AV, Shahripour RB, Barlinn K, Starkman S, Grunberg ID, et al. Feasibility and safety of using external counterpulsation to augment cerebral blood flow in acute ischemic stroke: the Counterpulsation to UpgradeForwardFlowinStroke(CUFFS)Trial.JStrokeCerebrovascDis. 235. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, et al; FAST- MAG Investigators and Coordinators. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528 236. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med. 2010;42:576 586. doi: 10.3109/07853890.2010.532811 237. StemerAB, Huisa BN, Zivin JA. The evolution of transcranial laser therapy 238. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, Fisher M, Hacke W, Holt W, Ilic S, et al; for the NeuroThera Effectiveness and Safety Trial-2 Investigators. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40:1359 1364. doi: 239. Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, Kasner SE, Shuaib A, Richieri SP, Dilly SG, et al; for the NEST 3 Committees and Investigators. Transcranial laser therapy in acute stroke treatment: results of Neurothera Effectiveness and Safety Trial 3, a phase III clinical end point device trial. Stroke. 2014;45:3187 240. Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarr a VV, Mu oz Venturelli P, Brunser A, Peng B, Cui L, et al; HeadPoSTInvestigatorsandCoordinators.Cluster-randomized,crossover trial of head positioning in acute stroke. N Engl J Med. 2017;376:2437 241. Alexandrov AW, Tsivgoulis G, Hill MD, Liebeskind DS, Schellinger P, Ovbiagele B, Arthur AS, Caso V, Nogueira RG, Hemphill JC 3rd, et al. HeadPoST: rightly positioned, or flat out wrong? Neurology. 242. Olavarr a VV, Lavados PM, Mu oz-Venturelli P, Gonz lez F, Gaete J, Martins S, Arima H, Anderson CS, Brunser AM. Flat-head positioning increases cerebral blood flow in anterior circulation acute ischemic stroke: a cluster randomized phase IIb trial. Int J Stroke. 2018;13:600 243. Stead LG, Gilmore RM, Vedula KC, Weaver AL, Decker WW, Brown RD Jr. Impact of acute blood pressure variability on is- chemic stroke outcome. Neurology. 2006;66:1878 1881. doi: 244. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke. 2001;32:461 465. doi: 10.1161/01.str.32.2.461 245. Schrader J, L ders S, Kulschewski A, Berger J, Zidek W, Treib J, Einh upl K, Diener HC, Dominiak P; on behalf of the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. 246. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling Hypertension and Hypotension Immediately Post- Stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot 247. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al; COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767 775. doi: 10.1016/S1474-4422(10)70163-0 248. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, et al; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479 489. 249. ENOS Trial Investigators, Bath PM, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treat- ment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet. 2015;385:617 628. 250. Kaste M, Fogelholm R, Eril T, Palom ki H, Murros K, Rissanen A, Sarna S.A randomized, double-blind, placebo-controlled trial of nimodip- ine in acute ischemic hemispheric stroke. Stroke. 1994;25:1348 1353. 251. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. The Intravenous Nimodipine West European Trial (INWEST) of nimodip- ine in the treatment of acute ischemic stroke. Cerebrovasc Dis. 1994;4:204 210. 252. Eveson DJ, Robinson TG, Potter JF. Lisinopril for the treatment of hyper- tension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens. 2007;20:270 277. doi: 10.1016/j.amjhyper.2006.08.005 253. Bath PM, Martin RH, PaleschY, Cotton D,Yusuf S, Sacco R, Diener HC, Toni D, Estol C, Roberts R; for the PRoFESS Study Group. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. 254. Sandset EC, Bath PM, Boysen G, Jatuzis D, K rv J, L ders S, Murray GD, Richter PS, Roine RO, Ter nt A, et al; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. 255. Bath PM, Krishnan K. Interventions for deliberately altering blood pres- sure in acute stroke. Cochrane Database Syst Rev. 2014:CD000039. 256. Oh MS, Yu KH, Hong KS, Kang DW, Park JM, Bae HJ, Koo J, Lee J, Lee BC; Valsartan Efficacy oN modesT blood pressUre REduction in acute ischemic stroke (VENTURE) study group. Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, random- ized, open-label, blinded-end-point trial. Int J Stroke. 2015;10:745 751. 257. LeeM,OvbiageleB,HongKS,WuYL,LeeJE,RaoNM,FengW,SaverJL. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. 258. Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, Wardlaw J, Sprigg N, Bath PM; on behalf of the ENOS Investigators. Effect of hyperacute administration (within 6 hours) of transdermal glyc- eryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial. Stroke. 259. Rai N, Prasad K, Bhatia R, Vibha D, Singh MB, Rai VK, Kumar A. Development and implementation of acute stroke care pathway in a ter- tiary care hospital in India: a cluster-randomized study. Neurol India. 260. Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D Este C, Drury P, Griffiths R, Cheung NW, Quinn C, et al; QASC Trialists Group. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378:1699 1706. doi: 261. Miles A, Zeng IS, McLauchlan H, Huckabee ML. Cough reflex testing in Dysphagia following stroke: a randomized controlled trial. J Clin Med 262. Joundi RA, Martino R, Saposnik G, Giannakeas V, Fang J, Kapral MK. Predictorsandoutcomesofdysphagiascreeningafteracuteischemicstroke. 263. S rensen RT, Rasmussen RS, Overgaard K, Lerche A, Johansen AM, Lindhardt T. Dysphagia screening and intensified oral hygiene re- duce pneumonia after stroke. J Neurosci Nurs. 2013;45:139 146. doi: 264. Brady M, Furlanetto D, Hunter RV, Lewis S, Milne V. Staff-led interven- tions for improving oral hygiene in patients following stroke. Cochrane Database Syst Rev. 2006:CD003864. 265. Wagner C, Marchina S, Deveau JA, Frayne C, Sulmonte K, Kumar S. Risk of stroke-associated pneumonia and oral hygiene. Cerebrovasc Dis. 266. Dennis M, Lewis S, Cranswick G, Forbes J; FOOD Trial Collaboration. FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke. Health Technol Assess. 2006;10:iii iv, ix. 267. Geeganage C, Beavan J, Ellender S, Bath PM. Interventions for dysphagia and nutritional support in acute and subacute stroke. Cochrane Database Syst Rev. 2012;10:CD000323. doi: 10.1002/14651858.CD000323.pub2 268. Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013;382:516 524. doi: 269. Dennis M, Caso V, Kappelle LJ, Pavlovic A, Sandercock P; European Stroke Organisation. European Stroke Organisation (ESO) guide- lines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016;1:6 19. doi: 270. Meader N, Moe-Byrne T, Llewellyn A, Mitchell AJ. Screening for poststroke major depression: a meta-analysis of diagnostic va- lidity studies. J Neurol Neurosurg Psychiatry. 2014;85:198 206. doi: 271. Berg A, L nnqvist J, Palom ki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. Stroke. 272. Kang HJ, Stewart R, Kim JM, Jang JE, Kim SY, Bae KY, Kim SW, Shin IS, Park MS, Cho KH, et al. Comparative validity of depression assessment scales for screening poststroke depression. J Affect Disord. 273. WilliamsLS,KroenkeK,BakasT,PlueLD,BrizendineE,TuW,HendrieH. Caremanagementofpoststrokedepression:arandomized,controlledtrial. 274. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, Kwa VI, Weisfelt M, Remmers MJ, ten Houten R, et al; PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. 275. Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A, Rebollo-Mesa I; STROKE-INF Investigators. Prophylactic anti- biotics after acute stroke for reducing pneumonia in patients with dys- phagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet. 2015;386:1835 1844. Powers et al 2019 Guidelines for Management of AIS e411 276. Liu L, Xiong XY, Zhang Q, Fan XT, Yang QW. The efficacy of prophy- lactic antibiotics on post-stroke infections: an updated systematic review and meta-analysis. Sci Rep. 2016;6:36656. doi: 10.1038/srep36656 277. Zheng F, Spreckelsen NV, Zhang X, Stavrinou P, Timmer M, Dohmen C, Goldbrunner R, Cao F, Zhang Q, Ran Q, et al. Should preventive antibiot- ics be used in patients with acute stroke? A systematic review and meta- analysis of randomized controlled trials. PLoS One. 2017;12:e0186607. 278. Vermeij JD, Westendorp WF, Dippel DW, van de Beek D, Nederkoorn PJ. Antibiotic therapy for preventing infections in people with acute stroke. Cochrane Database Syst Rev. 2018;1:CD008530. doi: 279. AVERT Trial Collaboration Group, Bernhardt J, Langhorne P, Lindley RI, ThriftAG,ElleryF,CollierJ,ChurilovL,MoodieM,DeweyH,DonnanG. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015;386:46 55. 280. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W; DECIMAL, DESTINY, and HAMLET Investigators. Early decompressive surgery in malignant infarc- tion of the middle cerebral artery: a pooled analysis of three ran- domised controlled trials. Lancet Neurol. 2007;6:215 222. doi: 281. Christensen MS, Paulson OB, Olesen J, Alexander SC, Skinhoj E, Dam WH, Lassen NA. Cerebral apoplexy (stroke) treated with or without prolonged artificial hyperventilation, 1: cerebral circu- lation, clinical course, and cause of death. Stroke. 1973;4:568 631. doi: 282. Ausina A, B guena M, Nadal M, Manrique S, Ferrer A, Sahuquillo J, Garnacho A. Cerebral hemodynamic changes during sustained hypocap- nia in severe head injury: can hyperventilation cause cerebral ischemia? Acta Neurochir Suppl. 1998;71:1 4. doi: 10.1007/978-3-7091-6475-4_1 283. Steiner LA, Balestreri M, Johnston AJ, Czosnyka M, Coles JP, Chatfield DA, Smielewski P, Pickard JD, Menon DK. Sustained mod- erate reductions in arterial CO2 after brain trauma time-course of cere- bral blood flow velocity and intracranial pressure. Intensive Care Med. 284. Carrera E, Steiner LA, Castellani G, Smielewski P, Zweifel C, Haubrich C, Pickard JD, Menon DK, Czosnyka M. Changes in cerebral compartmental compliances during mild hypocapnia in patients with traumatic brain injury. J Neurotrauma. 2011;28:889 896. doi: 285. Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg. 286. Wan YH, Nie C, Wang HL, Huang CY. Therapeutic hypothermia (differ- ent depths, durations, and rewarming speeds) for acute ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:2736 2747. doi: 287. Maciel CB, Sheth KN. Malignant MCA stroke: an update on surgical decompression and future directions. Curr Atheroscler Rep. 2015;17:40. 288. Yang MH, Lin HY, Fu J, Roodrajeetsing G, Shi SL, Xiao SW. Decompressive hemicraniectomy in patients with malignant middle ce- rebral artery infarction: a systematic review and meta-analysis. Surgeon. 289. Agarwalla PK, Stapleton CJ, Ogilvy CS. Craniectomy in acute is- chemic stroke. Neurosurgery. 2014;74(suppl 1):S151 S162. doi: 290. Alexander P, Heels-Ansdell D, Siemieniuk R, Bhatnagar N, Chang Y, FeiY, ZhangY, McLeod S, Prasad K, Guyatt G. Hemicraniectomy versus medical treatment with large MCA infarct: a review and meta-analysis. BMJ Open. 2016;6:e014390. doi: 10.1136/bmjopen-2016-014390 291. Sundseth J, Sundseth A, Jacobsen EA, Pripp AH, Sorteberg W, Altmann M, Lindegaard KF, Berg-Johnsen J, Thommessen B. Predictors of early in-hospital death after decompressive craniectomy in swollen middle cerebral artery infarction. Acta Neurochir (Wien). 2017;159:301 292. Suyama K, Horie N, Hayashi K, Nagata I. Nationwide survey of decompressive hemicraniectomy for malignant middle cerebral ar- tery infarction in Japan. World Neurosurg. 2014;82:1158 1163. doi: 293. Yu JW, Choi JH, Kim DH, Cha JK, Huh JT. Outcome following decom- pressive craniectomy for malignant middle cerebral artery infarction in patients older than 70 years old. J Cerebrovasc Endovasc Neurosurg. 294. J ttler E, Unterberg A, Woitzik J, B sel J, Amiri H, SakowitzOW,GondanM,SchillerP,LimprechtR,LuntzS,etal;DESTINY II Investigators. Hemicraniectomy in older patients with extensive mid- dle-cerebral-artery stroke. N Engl J Med. 2014;370:1091 1100. doi: 295. Zhao J, Su YY, Zhang Y, Zhang YZ, Zhao R, Wang L, Gao R, Chen W, Gao D. Decompressive hemicraniectomy in malignant middle cerebral ar- tery infarct: a randomized controlled trial enrolling patients up to 80 years old. Neurocrit Care. 2012;17:161 171. doi: 10.1007/s12028-012-9703-3 296. Raco A, Caroli E, Isidori A, Salvati M. Management of acute cerebellar infarction: one institution s experience. Neurosurgery. 2003;53:1061 297. Mostofi K. Neurosurgical management of massive cerebellar in- farct outcome in 53 patients. Surg Neurol Int. 2013;4:28. doi: 298. Heidenreich JO, Hsu D, Wang G, Jesberger JA, Tarr RW, Zaidat OO, Sunshine JL. Magnetic resonance imaging results can affect therapy decisions in hyperacute stroke care. Acta Radiol. 2008;49:550 557. doi: 299. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, Haynes RB, Sackett DL, PeerlessSJ,FergusonGG,FoxAJ,RankinRN,HachinskiVC,WiebersDO, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445 453. doi: 300. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351:1379 1387. 301. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 302. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1 13. 303. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996;348:1329 1339. doi: 304. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopido- grel for recurrent stroke. N Engl J Med. 2008;359:1238 1251. doi: 305. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345 1349. 306. PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033 307. Burke JF, Gelb DJ, Quint DJ, Morgenstern LB, Kerber KA. The impact of MRI on stroke management and outcomes: a systematic review. J Eval Clin Pract. 2013;19:987 993. doi: 10.1111/jep.12011 308. Wardlaw J, Brazzelli M, Miranda H, Chappell F, McNamee P, Scotland G, Quayyum Z, Martin D, Shuler K, Sandercock P, et al. An assessment of the cost-effectiveness of magnetic resonance, including diffusion- weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. Health Technol Assess. 2014;18:1 368, v vi. doi: 10.3310/hta18270 309. Ertl-Wagner B, Brandt T, Seifart C, Forsting M. Diagnostic and thera- peutic consequences of repeat brain imaging and follow-up vascular im- aging in stroke patients. AJNR Am J Neuroradiol. 1999;20:37 42. 310. Schneider LB, Libman RB, Kanner R. Utility of repeat brain imaging in stroke. AJNR Am J Neuroradiol. 1996;17:1259 1263. 311. S ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-KudskJE,SettergrenM,Sj strandC,RoineRO,Hildick-SmithD, et al; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 312. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, B jot Y, Vuillier F, Detante O, et al; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011 1021. doi: 313. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J 314. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-term out- comes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022 1032. doi: 10.1056/NEJMoa1610057 315. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, AndersenG,IbrahimR,SchulerG,WaltonAS,etal;PCTrialInvestigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083 1091. doi: 10.1056/NEJMoa1211716 316. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, et al; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991 999. doi: 317. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, et al. cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO Trial. J Am Coll Cardiol. 318. Turc G, Calvet D, Guerin P, Sroussi M, Chatellier G, Mas JL, CLOSE Investigators. Closure, anticoagulation, or antiplatelet therapy for crypto- genic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE Study. J Am Heart Assoc. 2018;7:e008356. doi: 10.1161/JAHA.117.008356 319. Mir H, Siemieniuk RAC, Ge L, Foroutan F, Fralick M, Syed T, Lopes LC, Kuijpers T, Mas JL, Vandvik PO, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta- analysis incorporating complementary external evidence. BMJ Open. 320. Qiu B, Cai Y, Wang D, Lin J, Fan Y. Closure versus medical therapy for patent foramen ovale in patients with cryptogenic stroke: an updated meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 321. Giacoppo D, Caronna N, Frangieh AH, Michel J, And G, Tarantini G, Kasel AM, Capodanno D, Byrne RA. Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrom- botic therapy alone: a meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data. EuroIntervention. 322. Niu X, Ou-Yang G, Yan PF, Huang SL, Zhang ZT, Zhang ZH. Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials. J Neurol. 323. Li J, Liu J, Liu M, Zhang S, Hao Z, Zhang J, Zhang C. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev. 2015:CD009938. 324. McIntyre WF, Spence J, Belley-Cote EP. Assessing the quality of ev- idence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. Eur Heart J. 2018;39:3618 3619. doi: 325. Ois A, Cuadrado-Godia E, Rodr guez-Campello A, Jimenez-Conde J, Roquer J. High risk of early neurological recurrence in symptomatic ca- rotid stenosis. Stroke. 2009;40:2727 2731. doi: 10.1161/STROKEAHA. 326. De Rango P, Brown MM, Chaturvedi S, Howard VJ, Jovin T, Mazya MV, Paciaroni M, Manzone A, Farchioni L, Caso V. Summary of evidence on early carotid intervention for recently symptomatic stenosis based on meta-analysis of current risks. Stroke. 2015;46:3423 3436. doi: Horgan G, Kyne L, Moroney J, McCormack PM, et al. Stroke recur- rence within the time window recommended for carotid endarterectomy. 328. Johansson EP, Arnerl v C, Wester P. Risk of recurrent stroke before ca- rotid endarterectomy: the ANSYSCAP study. Int J Stroke. 2013;8:220 329. Str mberg S, Nordanstig A, Bentzel T, sterberg K, Bergstr m GM. Risk of early recurrent stroke in symptomatic carotid stenosis. Eur J Vasc Endovasc Surg. 2015;49:137 144. doi: 10.1016/j.ejvs.2014.11.004 330. Kazandjian C, Kretz B, Lemogne B,Aboa Eboul C, B jotY, Steinmetz E. Influence of the type of cerebral infarct and timing of intervention in the early outcomes after carotid endarterectomy for symptomatic stenosis. J Vasc Surg. 2016;63:1256 1261. doi: 10.1016/j.jvs.2015.10.097 331. Azzini C, Gentile M, De Vito A, Traina L, Sette E, Fainardi E, Mascoli F, Casetta I. Very early carotid endarterectomy after intrave- nous thrombolysis. Eur J Vasc Endovasc Surg. 2016;51:482 486. doi: 332. Adachi K, Sadato A, Hayakawa M, Maeda S, Hirose Y. Acute carotid ar- tery stenting in symptomatic high-grade cervical carotid artery stenosis. Neurosurg Rev. 2017;40:45 51. doi: 10.1007/s10143-016-0737-4 333. Vasconcelos V, Cassola N, da Silva EM, Baptista-Silva JC. Immediate versus delayed treatment for recently symptomatic carotid ar- tery stenosis. Cochrane Database Syst Rev. 2016;9:CD011401. doi: Taylor DW, Haynes RB, Finan JW, Hachinski VC, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 335. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracra- nial arterial stenosis. N Engl J Med. 2005;352:1305 1316. doi: 336. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for in- tracranial arterial stenosis. N Engl J Med. 2011;365:993 1003. doi: 337. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 338. Lutsep HL, Barnwell SL, Larsen DT, Lynn MJ, Hong M, Turan TN, Derdeyn CP, Fiorella D, Janis LS, Chimowitz MI; for the SAMMPRIS Investigators. Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015;46:775 779. 339. Chaturvedi S, Turan TN, Lynn MJ, Derdeyn CP, Fiorella D, Janis LS, Chimowitz MI; for the SAMMPRIS Trial Investigators. Do patient char- acteristics explain the differences in outcome between medically treated patients in SAMMPRIS and WASID? Stroke. 2015;46:2562 2567. doi: 340. Kallm nzer B, Breuer L, Kahl N, Bobinger T, Raaz-Schrauder D, Huttner HB, Schwab S, K hrmann M. Serious cardiac arrhythmias after stroke: incidence, time course, and predictors: a systematic, prospec- tive analysis. Stroke. 2012;43:2892 2897. doi: 10.1161/STROKEAHA. 341. Fern ndez-Men ndez S, Garc a-Santiago R, Vega-Primo A, Gonz lez Nafr a N, Lara-Lezama LB, Redondo-Robles L, Montes-Montes M, Riveira-Rodr guez MC, Tejada-Garc a J. Cardiac arrhythmias in stroke unit patients: evaluation of the cardiac monitoring data. Neurologia. 2016;31:289 295. doi: 10.1016/j.nrl.2015.03.013 342. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255 1262. 343. Sposato LA, Cipriano LE, Saposnik G, Ru z Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 344. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478 2486. doi: 10.1056/NEJMoa1313600 345. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, Rymer M, Ziegler PD, Liu S, Passman RS. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the Cryptogenic Stroke and Underlying Powers et al 2019 Guidelines for Management of AIS e413 Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016;9:e003333. 346. Wachter R, Gr schel K, Gelbrich G, Hamann GF, Kermer P, LimanJ,SeegersJ,WasserK,SchulteA,J rriesF,etal;Find-AFRANDOMISED Investigators and Coordinators. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFrandomised): an open- label randomised controlled trial. Lancet Neurol. 2017;16:282 290. doi: 347. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL; IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagula- tion in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36:1660 1668. doi: 10.1093/eurheartj/ehv115 348. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O Donnell M, Laupacis A, C t R, et al; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467 2477. doi: 10.1056/NEJMoa1311376 349. Higgins P, Dawson J, MacFarlane PW, McArthur K, Langhorne P, Lees KR. Predictive value of newly detected atrial fibrillation paroxysms in patients with acute ischemic stroke, for atrial fibrillation after 90 days. 350. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Duley L, England TJ, Flaherty K, Havard D, et al; TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and di- pyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391:850 859. doi: 351. Meenan RT, Saha S, Chou R, Swarztrauber K, Krages KP, O Keefee-RosettiM,McDonaghM,ChanBK,HornbrookMC,HelfandM. Effectiveness and cost-effectiveness of echocardiography and carotid im- aging in the management of stroke. Evid Rep Technol Assess (Summ). 2002:1 10. Coutts SB. Acute ischaemic stroke or transient ischaemic attack and the need for inpatient echocardiography. Postgrad Med J. 2014;90:434 438. 353. Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P, Wang J. Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic re- view and economic evaluation. Health Technol Assess. 2014;18:1 176. 354. McGrath ER, Paikin JS, Motlagh B, Salehian O, Kapral MK, O Donnell MJ. Transesophageal echocardiography in patients with cryp- togenic ischemic stroke: a systematic review. Am Heart J. 2014;168:706 355. Zhang L, Harrison JK, Goldstein LB. Echocardiography for the de- tection of cardiac sources of embolism in patients with stroke or tran- sient ischemic attack. J Stroke Cerebrovasc Dis. 2012;21:577 582. doi: 356. Schaer B, Sticherling C, Lyrer P, Osswald S. Cardiological diagnostic work-up in stroke patients: a comprehensive study of test results and therapeutic implications. Eur J Neurol. 2009;16:268 273. doi: 357. DouenA, Pageau N, Medic S. Usefulness of cardiovascular investigations in stroke management: clinical relevance and economic implications. 358. Wolber T, Maeder M, Atefy R, Bluzaite I, Blank R, Rickli H, Ammann P. Should routine echocardiography be performed in all patients with stroke? J Stroke Cerebrovasc Dis. 2007;16:1 7. doi: 359. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR,Ammon SE, Graham S, Sacco RL, Mann DL, et al;WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859 1869. doi: 360. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O Connor CM, Schulman KA, et al; for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and AntiplateletTherapyinChronicHeartFailure(WATCH)trial.Circulation. 361. Ahmad O, Ahmad KE, Dear KB, Harvey I, Hughes A, Lueck CJ. Echocardiography in the detection of cardioembolism in a stroke popula- tion. J Clin Neurosci. 2010;17:561 565. doi: 10.1016/j.jocn.2009.09.016 362. Secades S, Mart n M, Corros C, Rodr guez ML, Garc a-Campos A, de la Hera Galarza JM, Lambert JL. Diagnostic yield of echocardiography in stroke: should we improve patient selection? Neurologia. 2013;28:15 363. Kapral MK, Silver FL. Preventive health care, 1999 update, 2: echocar- diography for the detection of a cardiac source of embolus in patients with stroke: Canadian Task Force on Preventive Health Care. CMAJ. 1999;161:989 996. 364. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J 365. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke. 2010;41:2985 366. Brown DL, Chervin RD, Hickenbottom SL, Langa KM, Morgenstern LB. Screening for obstructive sleep apnea in stroke patients: a cost-effectiveness analysis. Stroke. 2005;36:1291 1293. doi: 367. Pack AI, Pien GW. Update on sleep and its disorders. Annu Rev Med. 368. Medeiros CA, de Bruin VM, Andrade GM, Coutinho WM, de Castro-Silva C, de Bruin PF. Obstructive sleep apnea and biomarkers of inflammation in ischemic stroke. Acta Neurol Scand. 2012;126:17 22. 369. Camilo MR, Sander HH, Eckeli AL, Fernandes RM, Dos Santos-Pontelli TE, Leite JP, Pontes-Neto OM. SOS score: an opti- mized score to screen acute stroke patients for obstructive sleep apnea. Sleep Med. 2014;15:1021 1024. doi: 10.1016/j.sleep.2014.03.026 370. Stahl SM, Yaggi HK, Taylor S, Qin L, Ivan CS, Austin C, Ferguson J, Radulescu R, Tobias L, Sico J, et al. Infarct location and sleep apnea: evaluating the potential association in acute ischemic stroke. Sleep Med. P rez-Ronchel J, Dur n-Cantolla J, de la Torre G, Gonz lez Marcos JR, de la Pe a M, et al. Early treatment of obstructive apnoea and stroke out- come: a randomised controlled trial. Eur Respir J. 2011;37:1128 1136. 372. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, et al; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919 931. doi: 10.1056/NEJMoa1606599 373. C t R, Zhang Y, Hart RG, McClure LA, Anderson DC, Talbert RL, Benavente OR. ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology. 2014;82:382 374. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a sys- tematic review and meta-analysis. Stroke. 2017;48:2610 2613. doi: 375. John S, Katzan I. Recurrent stroke while on antiplatelet therapy. Neurol 376. Turan TN, Maidan L, Cotsonis G, Lynn MJ, Romano JG, Levine SR, ChimowitzMI;fortheWarfarin-AspirinSymptomaticIntracranialDisease Investigators. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009;40:505 377. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, Chaturvedi S, Levine SR, Stern BJ, Benesch CG, et al; Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 378. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibril- lation: effect of anticoagulation and its timing: the RAF Study. Stroke. 379. Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J; CADISS Trial Investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14:361 367. doi: 10.1016/ 380. Larsson SC, King A, Madigan J, Levi C, Norris JW, Markus HS. Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review. Neurology. 2017;88:646 652. doi: 381. Ahlhelm F, Benz RM, Ulmer S, Lyrer P, Stippich C, Engelter S. Endovascular treatment of cervical artery dissection: ten case reports and review of the literature. Interv Neurol. 2013;1:143 150. doi: 382. Kim JT, Heo SH, Park MS, Chang J, Choi KH, Cho KH. Use of anti- thrombotics after hemorrhagic transformation in acute ischemic stroke. PLoS One. 2014;9:e89798. doi: 10.1371/journal.pone.0089798 383. England TJ, Bath PM, Sare GM, Geeganage C, Moulin T, O Neill D, Woimant F, Christensen H, De Deyn P, Leys D, et al; TAIST Investigators. Asymptomatic hemorrhagic transformation of infarction and its relation- ship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke. 2010;41:2834 2839. 384. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ce ka R, Lepor N, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580 1590. doi: 10.1001/jama.2016.3608 385. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, et al; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechal- lenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin 386. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC, Jr. 2016 ACC ex- pert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardi- ovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 387. Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, Ovbiagele B. Achieving target cholesterol goals after stroke: is in-hos- pital statin initiation the key? Arch Neurol. 2006;63:1081 1083. doi: 388. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke. 2015;17:282 301. doi: 10.5853/jos.2015.17.3.282 389. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961 969. doi: 390. Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T; on behalf of the ASSORT Trial Investigator. Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke. 2017;48:3057 3063. doi: 391. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smok- ing cessation in hospitalised patients. Cochrane Database Syst Rev. 2012:CD001837. 392. Lee MJ, Park E, Kim HC, Lee HS, Cha MJ, Kim YD, Heo JH, Nam HS. Timely interventions can increase smoking cessation rate in men with ischemic stroke. J Korean Acad Nurs. 2016;46:610 617. doi: 393. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, et al; EVITA Investigators. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation. 2016;133:21 30. doi: 394. Schwartz J, Dreyer RP, Murugiah K, Ranasinghe I. Contemporary pre- hospital emergency medical services response times for suspected stroke in the United States. Prehosp Emerg Care. 2016;20:560 565. doi: 395. Boden-Albala B, Stillman J, Roberts ET, Quarles LW, Glymour MM, Chong J, Moats H, Torrico V, Parides MC. Comparison of acute stroke preparedness strategies to decrease emergency de- partment arrival time in a multiethnic cohort: the Stroke Warning Information and Faster Treatment Study. Stroke. 2015;46:1806 1812. 396. Morgenstern LB, Gonzales NR, Maddox KE, Brown DL, Karim AP, Espinosa N, Moy LA, Pary JK, Grotta JC, Lisabeth LD, et al.A random- ized, controlled trial to teach middle school children to recognize stroke and call 911: the Kids Identifying and Defeating Stroke project. Stroke. 397. Kidwell CS, Starkman S, Eckstein M, Weems K, Saver JL. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital 398. Bray JE, Martin J, Cooper G, Barger B, Bernard S, Bladin C. Paramedic identification of stroke: community validation of the Melbourne Ambulance Stroke Screen. Cerebrovasc Dis. 2005;20:28 33. doi: 399. Studnek JR,AsimosA, Dodds J, Swanson D.Assessing the validity of the CincinnatiPrehospitalStrokeScaleandtheMedicPrehospitalAssessment for Code Stroke in an urban emergency medical services agency. Prehosp Emerg Care. 2013;17:348 353. doi: 10.3109/10903127.2013.773113 400. Chenkin J, Gladstone DJ, Verbeek PR, Lindsay P, Fang J, Black SE, Morrison L. Predictive value of the Ontario prehospital stroke screening tool for the identification of patients with acute stroke. Prehosp Emerg 401. Asimos AW, Ward S, Brice JH, Rosamond WD, Goldstein LB, Studnek J. Out-of-hospital stroke screen accuracy in a state with an emergency med- ical services protocol for routing patients to acute stroke centers. Ann 402. Pickham D, Valdez A, Demeestere J, Lemmens R, Diaz L, Hopper S, de la Cuesta K, Rackover F, Miller K, Lansberg MG. Prognostic value of BEFAST vs. FAST to identify stroke in a prehospital setting. Prehosp Emerg Care. 2019;23:195 200. doi: 10.1080/10903127.2018.1490837 403. van Wijngaarden JD, Dirks M, Niessen LW, Huijsman R, Dippel DW. Do centres with well-developed protocols, training and infrastructure have higher rates of thrombolysis for acute ischaemic stroke? QJM. 404. Jeng JS, Tang SC, Deng IC, Tsai LK,Yeh SJ,Yip PK. Stroke center char- acteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan. J Neurol Sci. 2009;281:24 27. doi: 10.1016/j.jns.2009.03.004 405. Douglas VC, Tong DC, Gillum LA, Zhao S, Brass LM, Dostal J, Johnston SC. Do the Brain Attack Coalition s criteria for stroke centers improve care for ischemic stroke? Neurology. 2005;64:422 427. doi: 406. Asimos AW, Norton HJ, Price MF, Cheek WM. Therapeutic yield and outcomes of a community teaching hospital code stroke protocol. Acad Emerg Med. 2004;11:361 370. doi: 10.1197/j.aem.2003.12.016 407. Sauser K, Levine DA, Nickles AV, Reeves MJ. Hospital variation in thrombolysis times among patients with acute ischemic stroke: the con- tributions of door-to-imaging time and imaging-to-needle time. JAMA Dodick DW, Ward MP, Richemont PC, Brazdys K, et al; for the STRokE DOC AZ TIME Investigators. Stroke team remote evaluation using a dig- italobservationcamerainArizona:theinitialMayoClinicexperiencetrial. 409. Meyer BC, Raman R, Hemmen T, Obler R, Zivin JA, Rao R, Thomas RG, Lyden PD. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. 410. Rai AT, Smith MS, Boo S, Tarabishy AR, Hobbs GR, Carpenter JS. The pit-crew model for improving door-to-needle times in endovascular stroke therapy: a Six-Sigma project. J Neurointerv Surg. 2016;8:447 411. Muir KW, Ford GA, Messow CM, Ford I, Murray A, Clifton A, Brown MM, Madigan J, Lenthall R, Robertson F, et al; PISTE Investigators. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) ran- domised, controlled trial. J Neurol Neurosurg Psychiatry. 2017;88:38 412. Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, Frei D, Shownkeen H, Budzik R, Ajani ZA, et al; THERAPY Trial Investigators. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke. 2016;47:2331 2338. doi: 413. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893 903. doi: 414. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E; SYNTHESIS Expansion Investigators. Endovascular treat- ment for acute ischemic stroke. N Engl J Med. 2013;368:904 913. doi: Powers et al 2019 Guidelines for Management of AIS e415 415. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914 923. doi: 10.1056/NEJMoa1212793 416. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlu- sions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 417. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO; SWIFT Trialists. Solitaire flow restoration de- vice versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 418. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; for the MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke. 419. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, et al. Intra-arterial prouro- kinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism. JAMA. 420. Brazzelli M, Sandercock PA, Chappell FM, Celani MG, Righetti E, Arestis N,Wardlaw JM, Deeks JJ. 